Investor Overview

Corporate Profile
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), is a clinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to achieve meaningful levels of protection by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational product using CODIT™, AR101 for the treatment of peanut allergy, has... more >
Recent Newsmore >
April 13, 2017
Aimmune Therapeutics Appoints Eric Bjerkholt as Chief Financial Officer
— New CFO Is an Established Leader and Healthcare Industry Veteran — BRISBANE, Calif.--(BUSINESS WIRE)--Apr. 13, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), today announced the appointment of Eric Bjerkholt as Chief Financial Officer. Mr. Bjerkholt joins Aimmune from Sunesis Pharmaceuticals, Inc., where, over 13 years with the company, his role as CFO expanded to oversee multiple aspects of governance, corporate relations, and other ... 
March 15, 2017
Aimmune Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results
— Company Began 2017 with Approximately $283 Million in Cash and Investments, Sufficient to Support Current Development Plans through Regulatory Submissions — — Conference Call and Webcast Today at 8:00 a.m. ET — BRISBANE, Calif.--(BUSINESS WIRE)--Mar. 15, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food... 
March 8, 2017
Aimmune Therapeutics to Release Fourth Quarter and Full Year 2016 Financial Results on Wednesday, March 15, 2017
- Conference Call and Webcast to Follow at 8:00 a.m. ET/ 5:00 a.m. PT - BRISBANE, Calif.--(BUSINESS WIRE)--Mar. 8, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its financial results for the fourth quarter and full year 2016 will be released on Wednesday, March 15, 2017, before U.S. markets open. At 8:00 a.m. Eastern Time / 5:00 a.m. ... 
Upcoming Eventsmore >
There are currently no events scheduled.
Email Alerts
Sign up to receive email alerts when Aimmune Therapeutics posts new information to this site. Please enter your email address and click submit below.